Abcellera Biologics Inc (ABCL) Key Ratios

$11.57

up-down-arrow $0.21 (1.85%)

As on 03-Sep-2026 16:19EDT

Market cap

info icon

$3,678 Mln

Revenue (TTM)

info icon

$66 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

4.5

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -51.29 -76.29 101.28 -23.04 -31.77
EBIT -19.03 -28.48 23.59 -165.32 -191.36
Net Profit -28.41 -59.61 0.61 -66.00 -195.19
EPS -27.36 -55.93 2.53 -145.79 -194.77
Book Value -- -- -9.71 -7.53 4.54
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-25Dec-24
EBIT-Margin info -622.48-367.58-304.58-236.39-1,044.45
Net Margin info --11.41-248.83----
Return on equity info -13.83-5.54-17.68-14.47-14.75
Return on Capital info -12.83-5.08---13.12-13.85
Return on Assets info -10.63-4.20-11.64-10.78-11.43
Debt to Equity (x) info ----0.000.150.06
ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abcellera Biologics Inc (ABCL)
--
-13.12
-13.85
-11.50
13.31
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-17.68

Lower than Peers by 1.70

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abcellera Biologics Inc (ABCL)
-17.68
-14.47
-14.75
-12.27
14.03
Peer Median
-15.98
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-11.64

Higher than Peers by 0.21

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abcellera Biologics Inc (ABCL)
-11.64
-10.78
-11.43
-9.67
11.09
Peer Median
-11.85
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

-304.58

Lower than Peers by 277.52

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abcellera Biologics Inc (ABCL)
-304.58
-236.39
-1,044.45
-586.59
46.78
Peer Median
-27.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-248.83

Lower than Peers by 216.14

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abcellera Biologics Inc (ABCL)
-248.83
-194.88
-564.83
-385.00
31.20
Peer Median
-32.69
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

0.00

Lower than Peers by 0.00

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abcellera Biologics Inc (ABCL)
0.00
--
--
--
--
Peer Median
0.00
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Revenue Growth

101.28

Higher than Peers by 67.31

Year on year growth in net sales

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abcellera Biologics Inc (ABCL)
101.28
1.61
-0.24
-0.92
40.81
Peer Median
33.97
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

23.59

Higher than Peers by 48.85

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abcellera Biologics Inc (ABCL)
23.59
41.03
-35.01
-198.23
11,444.74
Peer Median
-25.26
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

0.61

Higher than Peers by 22.19

Year on year growth in profit after tax

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abcellera Biologics Inc (ABCL)
0.61
10.10
-11.24
-192.35
7,270.55
Peer Median
-21.58
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

2.53

Higher than Peers by 8.70

Year on year growth in earnings per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abcellera Biologics Inc (ABCL)
2.53
0.11
-0.10
-1.96
75.94
Peer Median
-6.17
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

-13.08

Lower than Peers by 10.19

Year on year growth in book value per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abcellera Biologics Inc (ABCL)
-13.08
--
--
--
--
Peer Median
-2.89
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abcellera Biologics Inc (ABCL)
--
0.15
0.06
0.07
0.07
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.01

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abcellera Biologics Inc (ABCL)
0.01
0.01
0.00
0.01
0.00
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

12.77

Higher than Peers by 3.66

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abcellera Biologics Inc (ABCL)
12.77
11.32
9.81
7.33
8.67
Peer Median
9.11
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

12.63

Higher than Peers by 3.52

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abcellera Biologics Inc (ABCL)
12.63
11.23
9.81
7.32
8.65
Peer Median
9.11
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

-11.19

Lower than Peers by 11.91

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abcellera Biologics Inc (ABCL)
-11.19
--
--
--
56.13
Peer Median
0.72
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

144.21

Higher than Peers by 121.45

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abcellera Biologics Inc (ABCL)
144.21
204.18
319.53
169.31
21.30
Peer Median
22.75
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.05

Lower than Peers by 0.01

Sales / Average Total Assets

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abcellera Biologics Inc (ABCL)
0.05
0.06
0.02
0.03
0.34
Peer Median
0.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abcellera Biologics Inc (ABCL)
--
596.85
991.33
805.86
104.69
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abcellera Biologics Inc (ABCL)
--
40.15
2.08
15.60
8.81
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abcellera Biologics Inc (ABCL)
--
377.52
112.70
238.45
81.78
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abcellera Biologics Inc (ABCL)
--
259.48
880.71
583.02
31.71
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abcellera Biologics Inc (ABCL)
--
-6.98
-5.30
-11.35
19.25
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

4.48

Lower than Peers by 0.35

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abcellera Biologics Inc (ABCL)
4.48
1.06
0.82
1.44
2.47
Peer Median
4.83
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abcellera Biologics Inc (ABCL)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

5.30

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abcellera Biologics Inc (ABCL)
5.30
-4.24
-1.48
-5.09
8.64
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

3,678

Higher than Peers by 3,461

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abcellera Biologics Inc (ABCL)
3,678
--
--
--
--
Peer Median
217
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...